Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.67 by 40.3 percent. This is a 114.24 percent increase over losses of $(6.60) per share from the same period last year. The company reported quarterly sales of $351.000 thousand which missed the analyst consensus estimate of $5.875 million by 94.03 percent.